ArticleAbdominal radiology (New York)2026
Intra-ablational and peri-ablational radiomics based on post-RFA gadoxetic acid disodium-enhanced MRI for predicting short-term prognosis in hepatocellular carcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the predictive value of intra-ablational and peri-ablational radiomics features extracted from the first post-RFA follow-up gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced MRI for short-term poor prognosis after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients, particularly for local tumor progression.
methodsA total of 181 HCC patients who underwent ultrasound-guided RFA at Lanzhou University First Hospital between 2017 and 2025 were retrospectively enrolled. Gd-EOB-DTPA-enhanced MRI and clinical data from the first post-RFA follow-up were collected. Short-term poor prognosis was defined as the appearance of new lesions within 6 months after RFA. Radiomics models based on MRI (arterial phase, portal venous phase, hepatobiliary phase) across various regions (entire ablation zone, Peri 3 mm, 5 mm, 7 mm) were developed using the LASSO approach and logistic regression. A combined model was constructed using best radiomics model features and clinical-radiological predictors. The performance, calibration and clinical utility were evaluated by ROC curve, calibration curve, and decision curve analysis, respectively.
resultsThe Peri 3 mm model achieved the best predictive performance among all radiomics models, with AUCs of 0.912 (95% CI: 0.836-0.961) and 0.856 (95% CI: 0.769-0.920) in the training and validation sets, respectively. The combined model integrating Peri 3 mm radiomics features, Log-AFP, and arterial phase peripheral enhancement showed AUCs of 0.948 (95% CI: 0.847-0.967) and 0.889 (95% CI: 0.728-0.934) in the training and validation sets. Exploratory evaluation in an independent testing set yielded consistent trends.
conclusionThe combined model incorporating Peri 3 mm radiomics feature and clinical-radiological risk factors has significant predictive value for short-term prognosis after RFA, particularly for local tumor progression, offering potential to optimize follow-up protocols and enable timely clinical decision-making for high-risk patients. However, given the limited number of short-term poor prognosis events in the independent testing set, this set is an exploratory evaluation and requires external validation in multi-center, large-sample cohorts.
Indexed as
Identifiers
42095900What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.